* product image indicative of product only, actual product may differ in appearance.
Compatible with Thrombin Time test on an analyzer.
Only takes 2 minutes. Identify DOACs rapidly.
New or direct oral anticoagulants (DOACs) include inhibitors of thrombin (eg. dabigatran) and factor Xa (eg. rivaroxaban, apixaban and edoxaban). The latter group are difficult to quantitate using current clotting methods and expensive chromogenic assays for the individual agents are in use.
The lupus anticoagulant-resistant dilute Russells viper venom test (dRVT-LR or "Confirm") has been suggested as a possible test method for all the DOACs since it is very sensitive to both classes of these inhibitors in vitro and in vivo and is less affected by extraneous variables such as heparins or low factor VIII levels than other clotting tests.
We guarantee a competitive price for our reagents.
1. Exner T, Ellwood L, Dangol M, Favaloro EJ. Mixing factor Xa and thrombin inhibiting direct oral anticoagulants produces a synergistic prolonging effect on most clotting tests. Int J Lab Hematol. 2023; 1-4.
2. Ten Cate H. Monitoring new oral anticoagulants, managing thrombosis or both? Thromb. Haemost. 2012; 107; 803-805.
3. Exner T, Ellwood L, Rubie J, Barancewicz A,. Testing for new oral anticoagulants with LA resistant Russell’s viper venom reagents. An in vitro study. Thromb. Haemost. 2013; 109; 762-5.
4. Altman R, Gonzalez CD. Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs. Thromb. J. 2014; 12; 7.
5. Sennesael AL, Exner T, Chatelain B, et al, An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants. Thromb Res. 2017; 157: 29-37.
6. Exner T, Michalopoulos N, Pearce J. et al. Simple method for removing DOACs from plasma samples. Throm.Res. 2018; 16:1028-39.
Use this form to send us a message.
*All fields are required.
